Merck And GE Healthcare Collaborate On Use Of Imaging Biomarkers For Investigational BACE Inhibitor Clinical Development Program

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2011 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site ( www.sec.gov).

¹ Alzheimer’s Disease International. Types of Dementia: Alzheimer’s Disease. Available at: http://www.alz.co.uk/info/alzheimers-disease.

² Alzheimer’s Disease International. Dementia Statistics. Available at: http://www.alz.co.uk/research/statistics.

³ Alzheimer’s Association. Alzheimer’s Fact and Figures. Available at: http://www.alz.org/alzheimers_disease_facts_and_figures.asp

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20121218005719/en/

Copyright Business Wire 2010

« First ‹ Previous 1 2 3 4